{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024737","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.122212+00:00","generated_at":"2026-06-21T20:53:28.513380+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tivic Health Q3 revenue up 72% to $477K; net loss $2.6M; agrees to acquire Reliefband for $33.5M","bullets":["Q3 2022 revenue $477K (+72% YoY); DTC unit sales up 130%; gross margin improved 22%.","Net loss $2.6M vs $2.3M in Q3 2021; cash and short-term investments $6.3M at Sept 30, 2022.","Entered asset purchase agreement for Reliefband (nausea treatment devices) for $33.5M cash; expected close Q4 2022/Q1 2023.","Manufacturing agreement with Microart to reduce ClearUP production costs; MSRP increased $20/unit."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024737","json":"https://secwatch.observer/filing/0000950170-22-024737.json","markdown":"https://secwatch.observer/filing/0000950170-22-024737.md","text":"https://secwatch.observer/filing/0000950170-22-024737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/tivc-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:53:28.513380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3cf320f659393a464eb640fec1308279a5d4a2bc","claim":"Valion Bio, Inc. reported the quarter ended September 30, 2022 results: revenue $477 thousand, net income $2.6 million.","evidence_excerpt":"Third Quarter 2022 Financial Highlights (as compared to the same periods in 2021) For the three months ended September 30, 2022: • Revenue increased 72% from $277 thousand to $477 thousand","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$477 thousand"},{"label":"Net income","value":"$2.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9212599fce38d64d4e125e1e6abd6a8326db89f2","claim":"Valion Bio, Inc. reported the nine months ended September 30, 2022 results: revenue $1.4 million.","evidence_excerpt":"For the nine months ended September 30, 2022: • Revenue increased $65% from $868 thousand to $1.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017022024737/0000950170-22-024737-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$1.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}